Clinical trial NCT03867253: Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
Official title: A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Mild to Moderate Alzheimer's Disease
Keywords: Alzheimer's Disease, ORY-2001
Lead sponsor: Oryzon Genomics S.A.
Sponsor class: INDUSTRY
Collaborators: name: Alzheimer's Drug Discovery Foundation
First posted: 2019-03-07
Enrollment: 24
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.

Detailed description: This phase IIa study is a double-blind, randomized, parallel-group and multicenter study with a placebo-controlled 24-week treatment period followed by a no placebo-controlled 24-week extension period.

It is planned to randomise 25 patients. In the double-blind placebo-controlled treatment period, all patients will be randomized between two doses of ORY-2001 and placebo. In the double-blind no placebo-controlled extension period, patients in the placebo arm will be re-allocated in one of the two different dose levels of ORY-2001. Randomization will be stratified by cognitive impairment severity.

An independent Data Monitoring Committee (DMC) will review un-blinded safety data throughout the study.

Eligibility criteria: Inclusion Criteria:

* Probable Alzheimer's Disease (AD) diagnosed according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
* MMSE score at Screening and Baseline Visits of at least 16 and not greater than 26
* Evidence of the AD pathophysiological process indicated by decreased levels of amyloid antigen binding (AB) and increased levels of total Tau protein or phospho-Tau protein in cerebrospinal fluid (CSF)
* Outpatient consulting a general practitioner, or a psychiatrist/neurologist/geriatrician
* Knowledgeable and reliable close relative/caregiver who will accompany the patient to all clinic visits during the study
* Daily treatment with the same acetylcholinesterase inhibitor on a stable dose
* Fertile male and female must use highly effective contraception, from the Screening Visit until 90 days after last dose.
* Signed informed consent by patient (or legal representative, if applicable) and a close relative/caregiver prior to the initiation of any study specific procedure

Exclusion Criteria:

* Failure to perform screening or baseline examinations
* Hospitalization or change of concomitant medication 1 month prior to Screening visit or during Screening Period
* Clinical, laboratory or neuroimaging findings consistent with:

  1. Other primary degenerative dementia;
  2. Other neurodegenerative condition;
  3. Cerebrovascular disease;
  4. Other central nervous system diseases;
* A current Diagnostic and Statistical Manual-5 (DSM-5) diagnosis of major depression, schizophrenia or bipolar disorder
* Positive results for tuberculosis, human immunodeficiency virus (HIV), hepatitis C or hepatitis B (hepatitis B surface antigen \[HbsAg\]) serology at the Screening Visit
* Clinically significant, advanced or unstable disease that may interfere with evaluation.
* Disability that may prevent the patients from completing all study requirements.
* Chronic drug intake of forbidden concomitant medication.
* Treatment with anti-amyloid beta or anti-Tau protein monoclonal antibodies or other disease modifying strategies within three months or five half-lives, whichever is longer, prior to the Screening Visit
* Treatment with an active vaccine targeting amyloid beta or Tau protein
* Suspected or known drug or alcohol abuse
* Metallic implants or any other cause precluding the performance of brain MRI
* Enrolment in another investigational study or intake of investigational drug within the previous 3 months since the last dose
* Suicide attempt within the last year or significant risk of suicide (in the opinion of the investigator, defined as a "yes" to suicidal ideation questions 4 or 5, or answering "yes" to suicidal behavior on the Columbia-Suicide Severity Rating Scale within the past 12 months)
* Any condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the study

Primary outcomes:
measure: Treatment Emergent Adverse Events
timeFrame: Week 24
measure: Treatment Emergent Adverse Events
timeFrame: Week 48
measure: Withdrawn patients due to TEAEs
timeFrame: Week 24
measure: Withdrawn patients due to TEAEs
timeFrame: Week 48
Secondary outcomes:
measure: Cohen-Mansfield Agitation Inventory (CMAI)
timeFrame: 48 weeks
measure: Clinician version of the Apathy Evaluation Scale (AES-C)
timeFrame: 48 weeks
measure: 14-item Alzheimer's Disease Assessment Scale-Cognitive
timeFrame: 48 weeks
measure: Computerized Cognitive Test battery
timeFrame: 48 weeks
measure: Mini-Mental State Examination (MMSE)
timeFrame: 48 weeks
measure: Clinical Dementia Rating Scale Sum of Boxes
timeFrame: 48 weeks
measure: Cornell Scale for Depression in Dementia (CSDD)
timeFrame: 48 weeks
Other outcomes:
Locations:
city: Wellington
country: United States
facility: Alzheimer's Research and Treatment Center
state: Florida
city: Columbus
country: United States
facility: Columbus Memory Center
state: Georgia
city: Princeton
country: United States
facility: Princeton Medical Institute
state: New Jersey
city: Willow Grove
country: United States
facility: Abington Neurological Associates Ltd.
state: Pennsylvania
Study officials:
affiliation: Oryzon Genomics S.A.
name: Michael Ropacki, MD
role: STUDY_DIRECTOR
References: